Partners

Academic Institutions

We collaborate closely with academic institutions, biotech and pharmaceutical companies and other organizations working on ALS and related fields.

 

Universities and research institutes are driving new ideas and identifying new targets for ALS. Target ALS is proud to partner with the following institutions:

  • Barrow Neurological Institute, Phoenix, AZ
  • Baylor College of Medicine, Houston, TX
  • Boston Children’s Hospital, Boston, MA
  • Brandeis University, Waltham, MA
  • Cedars–Sinai Medical Center, Los Angeles, CA
  • Columbia University, New York City, NY
  • Georgetown University, Washington, DC
  • Gladstone Institutes, San Francisco, CA
  • Harvard University, Cambridge, MA
  • Hôpital de la Pitié Salpétrière, Paris, France
  • INSERM, Paris, France
  • Johns Hopkins University, Baltimore, MD
  • Ludwig Institute for Cancer Research, San Diego, CA
  • Massachusetts General Hospital, Boston, MA
  • Mayo Clinic, Jacksonville, FL
  • Mayo Clinic, Rochester, MN
  • National Institute of Environmental Health, Research Triangle Park, NC
  • Northwestern University, Chicago, IL
  • Salk Institute for Biological Studies, La Jolla, CA
  • St. Jude Children’s Hospital, Memphis, TN
  • Stanford University, Stanford, CA
  • The Scripps Research Institute, Jupiter, FL
  • The Weizmann Institute of Science, Rehovot, Israel
  • Thomas Jefferson University, Philadelphia, PA
  • Ulster University, Belfast, UK
  • University of California, San Diego, CA
  • University of California, San Francisco, CA
  • University of Chicago, Chicago, IL
  • University of Florida Gainesville, FL
  • University of Massachusetts, Worcester, MA
  • University of Miami, Coral Gables, FL
  • University of Michigan, Ann Arbor, MI
  • University of North Carolina, Chapel Hill, NC
  • University of Oxford, Oxford, UK
  • University of Paris-Descartes, Paris, France
  • University Pennsylvania, Philadelphia, PA
  • University of Zurich, Zurich, Switzerland
  • Washington University, St. Louis, MO
  • University of Utah, Salt Lake City, UT
We could not do this alone. Partners are critical to the success of the Innovation Ecosystem.

BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES

Increasing industry involvement is a major goal for Target ALS, and we are pleased that many biotechnology and pharmaceutical companies as well as venture capital firms have joined our Innovation Ecosystem.

Representatives from the biomedical industry are collaborating within research consortia, serving as members of the Independent Review Committee, serving on our Board, participating in our Annual Meeting and engaging with us at all levels of strategic initiatives. We are grateful to the following:

  • AbbVie, North Chicago, IL
  • Aclipse Therapeutics, Radnor, PA
  • AcuraStem Inc., Monrovia, CA
  • ADRx, Inc., Westlake Village, CA
  • ALS Investment Fund, Amsterdam, Netherlands
  • Alsonex, Brisbane, Australia
  • Amgen, Thousand Oaks, CA
  • Amylyx Pharmaceuticals Inc., Cambridge, MA
  • Anida Pharma Inc., Cambridge, MA
  • Annexon Biosciences, South San Francisco, CA
  • Anida Pharma Inc., Cambridge, MA
  • AstraZeneca, London, UK
  • Aquinnah Pharmaceuticals, Cambridge, MA
  • Axxam SpA, Milan, Italy
  • Biogen, Cambridge, MA
  • Biohaven, New Haven, CT
  • Boehringer-Ingelheim, Ingelheim am Rhein, Germany
  • Bristol-Myers Squibb, New York City, NYClarus Ventures, Cambridge, MA
  • Congenia, Milan, Italy
  • CRISPR Therapeutics, Cambridge, MA
  • Denali Therapeutics, Cambridge, MA
  • Disarm Therapeutics, Cambridge, MA
  • F-Prime Capital Partners, Cambridge, MA
  • Genentech, South San Francisco, CA
  • Genzyme, Ridgefield, NJ
  • GlaxoSmithKline, Clifton, NJ
  • Inception Sciences, San Diego, CA
  • Intellia Therapeutics, Cambridge, MA
  • Ionis Pharmaceuticals, Carlsbad, CA
  • Izumi Biosciences, Lexington, MA
  • Karyopharm Therapeutics, MA
  • Lundbeck, Valby, Denmark
  • MeiraGTx, New York, NY
  • Merck, Kenilworth, NJ
  • miCure Therapeutics, Nes Ziona, Israel
  • Mitsubishi Tanabe, Japan
  • Neurimmune, Zurich, Switzerland
  • Neuroscience Technologies,
  • Novartis, New York City, NY
  • ONO Pharmaceutical Co., LTD., Osaka, Japan
  • OrbiMed Advisors LLC, New York, NY
  • Ossianix, Philadelphia, PA
  • Pfizer, Rye Brook, NY
  • Prosetta Biosciences, Inc, San Francisco, CA
  • Q Therapeutics, Salt Lake City, UT
  • QurAlis Corporation, Cambridge, MA
  • Regeneron, Tarrytown, NY
  • Revalesio Corporation, Tacoma, WA
  • Roche, Basel, Switzerland
  • Regulus, San Diego, CA
  • Sangamo Biosciences, Richmond, CA
  • Shire, Lexington, MA
  • Takeda, Osaka, Japan
  • Teva, Petah Tikva, Israel
  • Third Rock Ventures, Boston, MA
  • United Neuroscience, Dublin, Ireland
  • Verge Genomics, San Francisco, CA
  • Vertex, Boston, MA
  • Voyager Therapeutics, Cambridge, MA
  • WAVE Life Sciences, Cambridge, MA
  • Yumanity, Cambridge, MA

Foundations and other funders

Although for understandable reasons, the ALS research funding landscape in the past was divided between a number of excellent foundations and federal funding sources, there is an exciting and positive trend toward overall strategic consultation and partnership on specific initiatives.

From its launch, Target ALS has sought to collaborate, not to compete. We are delighted to be actively engaged in a mosaic of shared scientific and funding initiatives to get the important work done. Some of our key partners, today and over the past years, have been: